Violation Tracker Summary for Primary Offense Type

Offense Type: 
off-label or unapproved promotion of medical products
Penalty Total since 2000: 
$20,135,257,853
Number of Penalty Records: 
118
Note: 
The totals here are adjusted to account for the fact that each parent's entries may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. They are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the individual records list below.

Top 10 Parent CompaniesTotal Penalty $Number of Records
Pfizer$3,373,675,00010
Johnson & Johnson$3,136,000,00010
GlaxoSmithKline$3,004,361,8604
AbbVie$2,514,000,0007
Eli Lilly$1,608,100,0009
Merck$1,422,000,0007
Amgen$833,000,0003
Merck KGaA (EMD)$704,000,0002
AstraZeneca$594,000,0004
Bristol-Myers Squibb$534,500,0003


Individual Penalty Records:

Click on the company or penalty amount for more information on each case. Click on the parent name to reach the summary page for that parent company.
Download results as CSV or XML
Company Parent Parent Major Industrysort icon Year Agency Penalty Amount
Novartis Pharmaceuticals Novartis pharmaceuticals 2012 TX-AG $6,638,250
Novo Nordisk Inc. Novo Holdings A/S pharmaceuticals 2011 MULTI-AG (*) $3,574,209
Organon Merck pharmaceuticals 2014 MULTI-AG $31,000,000
Ortho-McNeil Pharmaceutical LLC Johnson & Johnson pharmaceuticals 2010 MULTI-AG (*) $24,681,516
Otsuka American Pharmaceutical Inc. Otsuka Pharmaceutical pharmaceuticals 2008 MULTI-AG (*) $1,700,000
Par Pharmaceutical Companies Inc. Endo International pharmaceuticals 2013 MULTI-AG (*) $22,500,000
Pfizer Pfizer pharmaceuticals 2014 MULTI-AG $35,000,000
Pfizer Inc. Pfizer pharmaceuticals 2008 MULTI-AG $60,000,000
Pfizer Inc. Pfizer pharmaceuticals 2013 MA-AG $375,000
Pfizer Inc. Pfizer pharmaceuticals 2012 MULTI-AG $42,900,000
Purdue Pharma Purdue Pharma pharmaceuticals 2007 MULTI-AG $19,500,000
Schering-Plough Corporation Merck pharmaceuticals 2006 MULTI-AG (*) $91,602,000
Serono Inc. Merck KGaA (EMD) pharmaceuticals 2005 MULTI-AG (*) $262,000,000
Shire Pharmaceuticals LLC Takeda Pharmaceutical pharmaceuticals 2014 MULTI-AG (*) $20,786,034
UCB Inc. UCB pharmaceuticals 2011 MULTI-AG (*) $9,893,322
Warner-Lambert Pfizer pharmaceuticals 2004 MULTI-AG (*) $190,000,000
Wyeth Pharmaceuticals, Inc. Pfizer pharmaceuticals 2013 MULTI-AG (*) $257,400,000
Novo Nordisk Inc. Novo Holdings A/S pharmaceuticals 2017 CA-INS $1,100,000
Download results as CSV or XML
(*): Some penalties are partial or complete duplicates of other penalty records, either because a DOJ settlement duplicates an agency record or because EPA listed the full penalty for a company for each of the company's relevant facilities. Penalty amounts marked with an asterisk have been identified by Good Jobs First as duplicating other penalty amounts.